Delcath Systems (OTCMKTS:DCTH) and Arch Therapeutics (OTCMKTS:ARTH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.
Institutional and Insider Ownership
0.0% of Arch Therapeutics shares are held by institutional investors. 4.2% of Delcath Systems shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This is a summary of recent recommendations and price targets for Delcath Systems and Arch Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Arch Therapeutics has a consensus target price of $1.63, suggesting a potential upside of 712.09%. Given Arch Therapeutics’ higher probable upside, analysts plainly believe Arch Therapeutics is more favorable than Delcath Systems.
This table compares Delcath Systems and Arch Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Delcath Systems and Arch Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Delcath Systems||$3.41 million||12.31||-$19.22 million||N/A||N/A|
|Arch Therapeutics||N/A||N/A||-$4.55 million||N/A||N/A|
Arch Therapeutics has lower revenue, but higher earnings than Delcath Systems.
Risk and Volatility
Delcath Systems has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the S&P 500.
Arch Therapeutics beats Delcath Systems on 7 of the 10 factors compared between the two stocks.
About Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
About Arch Therapeutics
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a product containing synthetic biocompatible peptides that comprise naturally occurring amino acids to achieve hemostasis in skin wounds and in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.